A citation-based method for searching scientific literature

Joaquin Mateo, Lotte Steuten, Philippe Aftimos, Fabrice André, Mark Davies, Elena Garralda, Jan Geissler, Don Husereau, Iciar Martinez-Lopez, Nicola Normanno, Jorge S Reis-Filho, Stephen Stefani, David M Thomas, C Benedikt Westphalen, Emile Voest. Nat Med 2022
Times Cited: 11

List of co-cited articles
11 articles co-cited >1

Times Cited
  Times     Co-cited

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro,[...]. Lancet Oncol 2022

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Leigh Marcus, Steven J Lemery, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2019

Review of precision cancer medicine: Evolution of the treatment paradigm.
Apostolia M Tsimberidou, Elena Fountzilas, Mina Nikanjam, Razelle Kurzrock. Cancer Treat Rev 2020

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020

The evolutionary dynamics and fitness landscape of clonal hematopoiesis.
Caroline J Watson, A L Papula, Gladys Y P Poon, Wing H Wong, Andrew L Young, Todd E Druley, Daniel S Fisher, Jamie R Blundell. Science 2020

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020

Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.
Nicola Normanno, Kathi Apostolidis, Francesco de Lorenzo, Philip A Beer, Raymond Henderson, Richard Sullivan, Andrew V Biankin, Denis Horgan, Mark Lawler. Semin Cancer Biol 2022

Precision Medicine in Phaeochromocytoma and Paraganglioma.
Bettina Winzeler, Benjamin G Challis, Ruth T Casey. J Pers Med 2021

Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature.
Camille Duhamel, Mirela Diana Ilie, Henri Salle, Adjoa Sika Nassouri, Stephan Gaillard, Elise Deluche, Richard Assaker, Laurent Mortier, Christine Cortet, Gérald Raverot. J Pers Med 2020

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question.
Vittoria Basile, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libè, Filippo Ceccato, Felix Beuschlein, Marcus Quinkler, Anna Calabrese, Paola Perotti,[...]. J Pers Med 2021

Next-generation therapies for adrenocortical carcinoma.
Barbara Altieri, Cristina L Ronchi, Matthias Kroiss, Martin Fassnacht. Best Pract Res Clin Endocrinol Metab 2020

Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies.
Anna Angelousi, Georgios K Dimitriadis, Georgios Zografos, Svenja Nölting, Gregory Kaltsas, Ashley Grossman. Endocr Relat Cancer 2017

Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications.
Marco Volante, Ida Rapa, Jasna Metovic, Francesca Napoli, Cristian Tampieri, Eleonora Duregon, Massimo Terzolo, Mauro Papotti. J Pers Med 2021

Needs, Preferences, and Values during Different Treatment Decisions of Patients with Differentiated Thyroid Cancer.
Anna Koot, Romana Netea-Maier, Petronella Ottevanger, Rosella Hermens, Peep Stalmeier. J Pers Med 2021

Integrated genomic characterization of adrenocortical carcinoma.
Guillaume Assié, Eric Letouzé, Martin Fassnacht, Anne Jouinot, Windy Luscap, Olivia Barreau, Hanin Omeiri, Stéphanie Rodriguez, Karine Perlemoine, Fernande René-Corail,[...]. Nat Genet 2014

New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
Matthew D Ringel. J Clin Endocrinol Metab 2021

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.
Siyuan Zheng, Andrew D Cherniack, Ninad Dewal, Richard A Moffitt, Ludmila Danilova, Bradley A Murray, Antonio M Lerario, Tobias Else, Theo A Knijnenburg, Giovanni Ciriello,[...]. Cancer Cell 2016

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer.
Tiziana Feola, Alessia Cozzolino, Roberta Centello, Carla Pandozzi, Maria Grazia Tarsitano, Elisa Giannetta. J Pers Med 2021

Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine.
Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari. J Pers Med 2021

The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms.
Anna Angelousi, Georgios Kyriakopoulos, Fani Athanasouli, Anastasia Dimitriadi, Eva Kassi, Chrysanthi Aggeli, George Zografos, Gregory Kaltsas. J Pers Med 2021

Metformin and reduced risk of cancer in diabetic patients.
Josie M M Evans, Louise A Donnelly, Alistair M Emslie-Smith, Dario R Alessi, Andrew D Morris. BMJ 2005

A quantitative analysis of kinase inhibitor selectivity.
Mazen W Karaman, Sanna Herrgard, Daniel K Treiber, Paul Gallant, Corey E Atteridge, Brian T Campbell, Katrina W Chan, Pietro Ciceri, Mindy I Davis, Philip T Edeen,[...]. Nat Biotechnol 2008

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Jordi Barretina, Giordano Caponigro, Nicolas Stransky, Kavitha Venkatesan, Adam A Margolin, Sungjoon Kim, Christopher J Wilson, Joseph Lehár, Gregory V Kryukov, Dmitriy Sonkin,[...]. Nature 2012

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Peter J Roberts, Michael C Heinrich, David A Tuveson, Samuel Singer, Milos Janicek,[...]. N Engl J Med 2002

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Vinod A Pullarkat, Norman J Lacayo, Elias Jabbour, Jeffrey E Rubnitz, Ashish Bajel, Theodore W Laetsch, Jessica Leonard, Susan I Colace, Seong Lin Khaw, Shaun A Fleming,[...]. Cancer Discov 2021

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Steven M Corsello, Rohith T Nagari, Ryan D Spangler, Jordan Rossen, Mustafa Kocak, Jordan G Bryan, Ranad Humeidi, David Peck, Xiaoyun Wu, Andrew A Tang,[...]. Nat Cancer 2020

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
João M Fernandes Neto, Ernest Nadal, Evert Bosdriesz, Salo N Ooft, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang,[...]. Nat Commun 2020

Clinical development success rates for investigational drugs.
Michael Hay, David W Thomas, John L Craighead, Celia Economides, Jesse Rosenthal. Nat Biotechnol 2014

Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability.
Paul E Harrington, Kaustav Biswas, David Malwitz, Andrew S Tasker, Christopher Mohr, Kristin L Andrews, Ken Dellamaggiore, Richard Kendall, Holger Beckmann, Peter Jaeckel,[...]. ACS Med Chem Lett 2014

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Vito Amodio, Rona Yaeger, Pamela Arcella, Carlotta Cancelliere, Simona Lamba, Annalisa Lorenzato, Sabrina Arena, Monica Montone, Benedetta Mussolin, Yu Bian,[...]. Cancer Discov 2020

High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Kristiina Iljin, Kirsi Ketola, Paula Vainio, Pasi Halonen, Pekka Kohonen, Vidal Fey, Roland C Grafström, Merja Perälä, Olli Kallioniemi. Clin Cancer Res 2009

The target landscape of clinical kinase drugs.
Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm, Harald Polzer, Binje Vick, Paul-Albert Koenig, Maria Reinecke, Benjamin Ruprecht, Svenja Petzoldt, Chen Meng,[...]. Science 2017

A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Hovav Nechushtan, Yousef Hamamreh, Salim Nidal, Maya Gotfried, Amichai Baron, Yossi Israeli Shalev, Benjjamin Nisman, Tamar Peretz, Nili Peylan-Ramu. Oncologist 2015

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, Ann S LaCasce, John F Gerecitano, John P Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi-Lin Chiu,[...]. Lancet Oncol 2010

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Erin F Cobain, Yi-Mi Wu, Pankaj Vats, Rashmi Chugh, Francis Worden, David C Smith, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva,[...]. JAMA Oncol 2021

Thalidomide-induced teratogenesis: history and mechanisms.
Neil Vargesson. Birth Defects Res C Embryo Today 2015

Metformin in cancer prevention and therapy.
Jacek Kasznicki, Agnieszka Sliwinska, Józef Drzewoski. Ann Transl Med 2014

Tumour-agnostic therapies.
Ann-Marie Looney, Khurram Nawaz, Rachel M Webster. Nat Rev Drug Discov 2020

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.